v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (971,322) $ (1,367,659)
Stock-based compensation expense included in -    
General and administrative costs 102,927 276,980
Research and development costs
Increase (decrease) in -    
Advances on research and development contract services 15,823
Prepaid insurance (5,678) (5,995)
Other prepaid expenses (64,130) (45,719)
Accounts payable and accrued expenses 89,929 (6,133)
Research and development contract liabilities 59,049 (138,666)
Net cash used in operating activities (789,225) (1,271,369)
Cash flows from financing activities:    
Exercise of common stock options 6,281
Net cash provided by financing activities 6,281
Cash:    
Net decrease (789,225) (1,265,088)
Balance at beginning of period 4,203,488 5,353,392
Balance at end of period 3,414,263 4,088,304
Supplemental disclosures of cash flow information:    
Interest 7,186 3,861
Income taxes

Source